Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
COSMOS Pharmaceutical Corporation ( (JP:3349) ) has issued an announcement.
COSMOS Pharmaceutical reported consolidated net sales of ¥537.2 billion for the six months ended November 30, 2025, up 6.2% year on year, with operating profit rising 1.6% to ¥20.7 billion and profit attributable to owners of parent increasing 1.5% to ¥14.6 billion, indicating continued but moderating earnings growth following a strong prior-year comparison. The company’s financial position remained solid, with total assets of ¥542.7 billion and an equity ratio of 49.6%, and it maintained its full-year forecast for the fiscal year ending May 31, 2026, projecting modest profit growth and annual dividends of ¥75 per share, underscoring stable shareholder returns and steady, if slower, expansion in a mature domestic retail market.
The most recent analyst rating on (JP:3349) stock is a Buy with a Yen9500.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.
More about COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation is a Japan-based drugstore operator listed on the Tokyo Stock Exchange, focusing on the retail sale of pharmaceuticals, daily necessities and related products. The company targets domestic consumers through a chain-store model, positioning itself as a volume retailer in the Japanese healthcare and daily goods market.
Average Trading Volume: 488,833
Technical Sentiment Signal: Buy
Current Market Cap: Yen608.3B
For an in-depth examination of 3349 stock, go to TipRanks’ Overview page.